Sanofi Ends Trial for E. Coli Shot and Takes a $250 Million Hit
Sanofi and Johnson & Johnson ended development of an experimental vaccine after it failed to adequately protect against an ...
pharmaphorum3d
Sanofi will exit consumer health and boost R&D investment
In its third-quarter results update, Sanofi said the consumer health unit – which owns brands like allergy therapies Allegra and Xyzal, irritable bowel syndrome product Buscopan, painkiller ...
Sanofi in exclusive talks with CD&R over sale of $17 bn Opella
Allegra allergy treatments and Buscopan pain relief. Sanofi, which said a year ago it was reviewing separation scenarios for ...
Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Bullous Pemphigoid
Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...
Business Insider India8y
Sanofi and Boehringer Ingelheim seek CCI’s clearance for global asset swap deal worth $25 billion
Sanofi and Boehringer Ingelheim (BI), drug giants ... with Ahmedabad-based Zydus Cadila for two gastrointestinal brands Buscopan and Dulcolax, re-launching those as Buscogast and Dulcoflex.